D4981C00001: A Phase 1b/2, Open-label Study to Evaluate the Safety & Tolerability of MEDI6469 in Combination w/ Immune Therapeutic Agents or Therapeutic Monoclonal Antibodies in Subjects w/ Selected Advanced Solid Tumors or Aggressive B-cell Lymphomas

December 31, 2014
Cancer - Breast, Cancer - Gastro, Cancer - Genitourinary/ Prostate/ Kidney, Cancer - Head and Neck, Cancer - Lymphoma, Cancer - Lung, Cancer Genitourinary/ Bladder, Cancer - Breast/ Gastro/ Lung/ Lymphoma/ Thyroid, Cancer - Gastro/ Colorectal, Cancer - Gynecologic/ Ovarian, Cancer - Gastro/ Esophageal, Cancer - Breast/ Genitourinary Prostate/ Lung, Cancer Genitourinary/ Prostate, Cancer - Genitourinary/ Bladder/ Prostate/ Urothel, Cancer - Pancreatic
Principal Investigator: Ding Wang, MD

The main purpose of this study is to determine the best dose of the experimental drug, MEDI6469 that is safe and tolerable when given in combination with tremelimumab, MEDI4736, or rituximab in subjects with either advanced solid tumors or diffuse large B-cell lymphoma (DLBCL).

Histologically or cytologically confirmed advanced solid tumors that are refractory to standard therapy or for which no standard therapy exists. Must provide consent for biopsy samples. Those with Squamous Cell Carcinoma of the Head and Neck (SCCHN) must have had the cancer spread from the primary site to other parts of the body or have failed to respond to or relapsed and who have received at least one platinum-based treatment for recurrent or metastatic disease. Those with Non Small Cell Lung Cancer (NSCLC) must have received 1 or 2 prior lines of therapy or that failed to respond to, relapsed or were unable to tolerate standard treatment.

Tiffany Pearce
(313) 916-1784